Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026)

Vivos Therapeutics' (VVOS) quarterly Debt Ratio came in at 0.31 in Q1 2026, down 12.14% on a QoQ basis from 0.35 in Q4 2025.

Vivos Therapeutics (VVOS) Debt Ratio (2019 - 2026) Analysis & Trends

Vivos Therapeutics (VVOS) has 5 years of Debt Ratio data on file, last reported at 0.31 in Q1 2026.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.31 in Q1 2026; TTM through Mar 2026 was 0.31, a N/A change from a year earlier, with the FY2025 full-year figure at 0.35, changed N/A from the prior year.
Debt Ratio for Q1 2026 stood at 0.31, down from 0.35 in the prior quarter.
Over the last five years, Debt Ratio for VVOS reached as high as 0.35 in Q4 2025 and fell as low as 0.3 in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	0.31
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	0.32
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	0.30
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	0.04
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	0.27
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	0.30
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	0.30
10	Vivos Therapeutics	5.92 Mn	3.81 Mn	3.06 Mn	0.31

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.31
Dec 31, 2025	0.35
Sep 30, 2025	0.34
Jun 30, 2025	0.30
Dec 31, 2021	0.04
Sep 30, 2021	0.06
Jun 30, 2021	0.05
Mar 31, 2021	0.06
Dec 31, 2020	0.05
Dec 31, 2019	0.49